 |
 |
|
15 June 1996 | Volume 124 Issue 12 | Pages 1039-1050
Objective: To evaluate the efficacy and safety of high-dose therapy with the human immunodeficiency virus (HIV) protease inhibitor saquinavir and to establish the duration of the effect of this therapy.
Design: Open-label study.
Setting: Clinical research referral center.
Patients: 40 adults with human immunodeficiency virus type 1 (HIV-1) infection and CD4+ T-cell counts of 200 to 500 cells/mm3.
Intervention: Monotherapy with 3600 mg or 7200 mg of saquinavir per day, in six divided doses, for 24 weeks.
Measurements: Patients were monitored for adverse events and were evaluated monthly for CD4+ T-cell count, HIV-1 viral load (as measured by reverse transcriptase polymerase chain reaction [PCR] for plasma HIV RNA levels), immune-complex-disassociated p24 antigen levels, peripheral blood mononuclear cell viral DNA levels (as measured by PCR), and resistance mutations to saquinavir. Quantitative peripheral blood mononuclear cell cultures were also done every 2 months.
Results: The low-dose saquinavir regimen (3600 mg/d) resulted in a maximal mean decrease in plasma HIV RNA levels of 1.06 log RNA copies/mL of plasma and a mean maximal increase in CD4 counts of 72 cells/mm3. At week 24, the plasma HIV RNA level remained 0.48 log RNA copies/mL of plasma lower than baseline (P < 0.001) and the CD4 count remained 31 cells/mm3 higher than baseline (P = 0.165). The high-dose saquinavir regimen (7200 mg/d) produced a mean maximal decrease in the plasma HIV RNA level of 1.34 log RNA copies/mL of plasma and a mean maximal increase in CD4 count of 121 cells/mm3. At week 24, the plasma HIV RNA level remained 0.85 log RNA copies/mL of plasma lower than baseline (P < 0.001) and the CD4 count remained 82 cells/mm3 higher than baseline (P = 0.002). The high-dose regimen produced a greater reduction in plasma HIV RNA level (P = 0.08), a greater reduction in peripheral blood mononuclear cell cultures (P = 0.008), and a greater increase in CD4 count (P = 0.002) than did the low-dose regimen. Higher plasma drug concentrations in individual patients correlated with greater reductions in plasma HIV RNA levels over the two doses. Nine patients receiving the low-dose regimen and four patients receiving the high-dose regimen developed key saquinavir resistance mutations. Adverse reactions, most commonly gastrointestinal problems and elevated serum aminotransferase levels, were more common in patients receiving the high-dose regimen, but most adverse events were mild and all were reversible.
Conclusion: Saquinavir is a potent antiviral agent that has a favorable toxicity profile at high doses. Higher doses produce a greater and more durable suppression of viral load and elevation in CD4+ T-cell counts and may delay the development of resistance mutations. Therapy with high-dose saquinavir alone or in combination with other antiretroviral agents should be investigated further.
Author and Article Information
For author affiliations and current author addresses, see end of text.
ARTICLE
The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients
Acknowledgments: The authors thank Drs. Cheryl Karol, Richard Ginsberg, and Miklos Salgo (Roche Pharmaceuticals, Inc., Nutley, New Jersey) for their support, Patricia Cain for clinical assistance, and Shannon Crawford, Kathy Richmond, and Teri Banks for technical assistance.
Grant Support: By Hoffmann-LaRoche and grant GCRC RR00070 from the National Institutes of Health. Roche Products had no influence on the gathering of the data, the interpretation of the data, or the reporting of the results, which were all the responsibility of the primary investigator, Dr. Merigan. Dr. Merigan has no financial interest in saquinavir or in Roche Products.
Requests for Reprints: Thomas C. Merigan, MD, Center For AIDS Research, S-156 Grant Building, Stanford University, Stanford, CA 94305.
Current Author Addresses: Dr. Schapiro: Division of Infectious Diseases, Room S-156, 300 Pasteur Drive, Stanford University School of Medicine, Stanford, CA 94305-5107.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. Marin-Niebla, L. F. Lopez-Cortes, R. Ruiz-Valderas, P. Viciana, R. Mata, A. Gutierrez, R. Pascual, and M. Rodriguez Clinical and Pharmacokinetic Data Support Once-Daily Low-Dose Boosted Saquinavir (1,200 Milligrams Saquinavir with 100 Milligrams Ritonavir) in Treatment-Naive or Limited Protease Inhibitor-Experienced Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2035 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Boston and J. C. Slish Management of HIV Infection in Persons Co-infected With Hepatitis Journal of Pharmacy Practice, August 1, 2005; 18(4): 295 - 309. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Stein, Y. Lou, M. Johnson, S. Randall, S. Blanche, and for the Prob2004 Study Team Pharmacokinetic and Pharmacodynamic Analysis of Amprenavir-Containing Combination Therapy in HIV-1-Infected Children J. Clin. Pharmacol., November 1, 2004; 44(11): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ahdieh-Grant, R. Li, A. M. Levine, L. S. Massad, H. D. Strickler, H. Minkoff, M. Moxley, J. Palefsky, H. Sacks, R. D. Burk, et al. Highly Active Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women J Natl Cancer Inst, July 21, 2004; 96(14): 1070 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Wu, C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments J. Virol., April 15, 2003; 77(8): 4836 - 4847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ahdieh-Grant, T. E. Yamashita, J. P. Phair, R. Detels, S. M. Wolinsky, J. B. Margolick, C. R. Rinaldo, and L. P. Jacobson When to Initiate Highly Active Antiretroviral Therapy: A Cohort Approach Am. J. Epidemiol., April 15, 2003; 157(8): 738 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hsu, J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, et al. Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., January 1, 2003; 47(1): 350 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Khoo, P. G. Hoggard, I. Williams, E. R. Meaden, P. Newton, E. G. Wilkins, A. Smith, J. F. Tjia, J. Lloyd, K. Jones, et al. Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3228 - 3235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Yeni, S. M. Hammer, C. C. J. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, et al. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel JAMA, July 10, 2002; 288(2): 222 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Jacobson, R. Li, J. Phair, J. B. Margolick, C. R. Rinaldo, R. Detels, and A. Munoz Evaluation of the Effectiveness of Highly Active Antiretroviral Therapy in Persons with Human Immunodeficiency Virus using Biomarker-based Equivalence of Disease Progression Am. J. Epidemiol., April 15, 2002; 155(8): 760 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Shafer Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sale, B. M. Sadler, and D. S. Stein Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir Antimicrob. Agents Chemother., March 1, 2002; 46(3): 746 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S J Gange, Y Barron, R M Greenblatt, K Anastos, H Minkoff, M Young, A Kovacs, M Cohen, W A Meyer III, and A Munoz Effectiveness of highly active antiretroviral therapy among HIV-1 infected women J Epidemiol Community Health, February 1, 2002; 56(2): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Tarwater, J. Mellors, M. E. Gore, J. B. Margolick, J. Phair, R. Detels, and A. Munoz Methods to Assess Population Effectiveness of Therapies in Human Immunodeficiency Virus Incident and Prevalent Cohorts Am. J. Epidemiol., October 1, 2001; 154(7): 675 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. Kakuda, L. M. Page, P. L. Anderson, K. Henry, T. W. Schacker, F. S. Rhame, E. P. Acosta, R. C. Brundage, and C. V. Fletcher Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir Antimicrob. Agents Chemother., January 1, 2001; 45(1): 236 - 242. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Kilby, G. Sfakianos, N. Gizzi, P. Siemon-Hryczyk, E. Ehrensing, C. Oo, N. Buss, and M. S. Saag Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2672 - 2678. [Abstract] [Full Text]
|
|
|
|
|
|
Y.-F. Gong, B. S. Robinson, R. E. Rose, C. Deminie, T. P. Spicer, D. Stock, R. J. Colonno, and P.-f. Lin In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632 Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2319 - 2326. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. B. Washington, H. R. Wiltshire, M. Man, T. Moy, S. R. Harris, E. Worth, P. Weigl, Z. Liang, D. Hall, L. Marriott, et al. The Disposition of Saquinavir in Normal and P-glycoprotein Deficient Mice, Rats, and in Cultured Cells Drug Metab. Dispos., September 1, 2000; 28(9): 1058 - 1062. [Abstract] [Full Text]
|
|
|
|
|
|
S. Sei, Q.-e. Yang, D. O'Neill, K. Yoshimura, K. Nagashima, and H. Mitsuya Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within the gag-pol Transframe Domain J. Virol., May 15, 2000; 74(10): 4621 - 4633. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Paredes, A. Mocroft, O. Kirk, A. Lazzarin, S. E. Barton, J. van Lunzen, T. L. Katzenstein, F. Antunes, J. D. Lundgren, B. Clotet, et al. Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe: Results From the EuroSIDA Study Arch Intern Med, April 24, 2000; 160(8): 1123 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Remmel, S. P. Kawle, D. Weller, and C. V. Fletcher Simultaneous HPLC Assay for Quantification of Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Plasma Clin. Chem., January 1, 2000; 46(1): 73 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Zolopa, R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed Ann Intern Med, December 7, 1999; 131(11): 813 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palmer, R. W. Shafer, and T. C. Merigan Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2046 - 2050. [Abstract] [Full Text]
|
|
|
|
|
|
R. W. Shafer, P. Hsu, A. K. Patick, C. Craig, and V. Brendel Identification of Biased Amino Acid Substitution Patterns in Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Protease Inhibitors J. Virol., July 1, 1999; 73(7): 6197 - 6202. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Zazzi, L. Romano, M. Catucci, G. Venturi, A. De Milito, and P. E. Valensin Clinical Evaluation of an In-House Reverse Transcription-Competitive PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma J. Clin. Microbiol., February 1, 1999; 37(2): 333 - 338. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. M. Gray, J. Lawrence, J. M. Schapiro, J. D. Altman, M. A. Winters, M. Crompton, M. Loi, S. K. Kundu, M. M. Davis, and T. C. Merigan Frequency of Class I HLA-Restricted Anti-HIV CD8+ T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART) J. Immunol., February 1, 1999; 162(3): 1780 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hsu, G. R. Granneman, G. Cao, L. Carothers, A. Japour, T. El-Shourbagy, S. Dennis, J. Berg, K. Erdman, J. M. Leonard, et al. Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2784 - 2791. [Abstract] [Full Text]
|
|
|
|
|
|
C. Solas, Y.-F. Li, M.-Y. Xie, J.-P. Sommadossi, and X.-J. Zhou Intracellular Nucleotides of (-)-2',3'-Deoxy-3'-Thiacytidine in Peripheral Blood Mononuclear Cells of a Patient Infected with Human Immunodeficiency Virus Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2989 - 2995. [Abstract] [Full Text]
|
|
|
|
|
|
A. K. Patick and K. E. Potts Protease Inhibitors as Antiviral Agents Clin. Microbiol. Rev., October 1, 1998; 11(4): 614 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Patick, M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir Antimicrob. Agents Chemother., October 1, 1998; 42(10): 2637 - 2644. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Winters, J. M. Schapiro, J. Lawrence, and T. C. Merigan Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment J. Virol., June 1, 1998; 72(6): 5303 - 5306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Owens, M. L. Brandeau, and C. H. Sox Effect of Relapse to High-Risk Behavior on the Costs and Benefits of a Program to Screen Women for Human Immunodeficiency Virus Interfaces, May 1, 1998; 28(3): 52 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Flexner HIV-Protease Inhibitors N. Engl. J. Med., April 30, 1998; 338(18): 1281 - 1293. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rasnick and D. Rasnick Kinetics Analysis of Consecutive HIV Proteolytic Cleavages of the Gag-Pol Polyprotein J. Biol. Chem., March 7, 1997; 272(10): 6348 - 6353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Cohn Recent advances: hiv infection–I BMJ, February 15, 1997; 314(7079): 487 - 487. [Full Text]
|
|
|
|
|
|
S. M. Hammer, D. A. Katzenstein, M. D. Hughes, H. Gundacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Niu, et al. A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter N. Engl. J. Med., October 10, 1996; 335(15): 1081 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Corey and K. K. Holmes Therapy for Human Immunodeficiency Virus Infection -- What Have We Learned? N. Engl. J. Med., October 10, 1996; 335(15): 1142 - 1144. [Full Text]
|
|
|
|
 |
|
 High-Dose Saquinavir Evaluated AIDS Clinical Care, August 1, 1996; 1996(801): 7 - 7. [Full Text]
|
|
Article
